Ilyang Pharmaceutical Co Ltd (007575) — Cash Flow-to-Debt Ratio
Ilyang Pharmaceutical Co Ltd (007575) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2025, meaning its operating cash flow of ₩2.26 Billion could theoretically repay 0% of its total liabilities (₩205.41 Billion) in one year. Explore Ilyang Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ilyang Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Ilyang Pharmaceutical Co Ltd across 11 annual periods. Also explore balance sheet size of Ilyang Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Ilyang Pharmaceutical Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Ilyang Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Ilyang Pharmaceutical Co Ltd market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩5.61 Billion | ₩189.63 Billion | ▼ -67.5% |
| 2023 | 0.09x | ₩14.62 Billion | ₩160.25 Billion | ▼ -37.1% |
| 2022 | 0.15x | ₩29.94 Billion | ₩206.33 Billion | ▼ -51.8% |
| 2021 | 0.30x | ₩67.02 Billion | ₩222.51 Billion | ▲ +1.8% |
| 2020 | 0.30x | ₩57.48 Billion | ₩194.19 Billion | ▲ +75.6% |
| 2019 | 0.17x | ₩36.19 Billion | ₩214.72 Billion | ▲ +69.5% |
| 2018 | 0.10x | ₩22.12 Billion | ₩222.37 Billion | ▼ -25.3% |
| 2017 | 0.13x | ₩30.03 Billion | ₩225.39 Billion | ▲ +5.6% |
| 2016 | 0.13x | ₩26.98 Billion | ₩213.91 Billion | ▼ -30.9% |
| 2015 | 0.18x | ₩40.27 Billion | ₩220.62 Billion | ▲ +142.4% |
| 2014 | 0.08x | ₩18.63 Billion | ₩247.37 Billion | — |